Insmed Incorporated

700 US Highway 202/206
Bridgewater
New Jersey
08807
United States

Tel: (908)977-9900

About Insmed Incorporated

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients living with serious and rare diseases. Our most valuable resource is our employees, and everything we do is motivated by a patients-first mentality. We are dedicated to growing our team with talented individuals from around the world who are willing to challenge the status quo, solve problems, and work collaboratively with a sense of urgency and compassion.

Guided by our core values of collaboration, accountability, passion, respect, and integrity, we aim to foster an inclusive, diverse, and flexible work environment, where our employees are recognized for leaning in and rolling up their sleeves. If you share our vision and want to work with the most dedicated people in the biopharma industry, come to Insmed to accelerate your career.

CONNECT

455 articles about Insmed Incorporated

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)-October 6, 2023

10/6/2023

Insmed Incorporated today announced the granting of inducement awards to 16 new employees.
Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference

9/26/2023

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at Chardan's 7th Annual Genetic Medicines Conference in New York, on Tuesday, October 3, 2023 at 2:00 p.m. ET.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - September 08, 2023

9/8/2023

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 13 new employees.
Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference

9/6/2023

Insmed Incorporated today announced that management will present in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, on Monday, September 11, 2023.
Insmed Announces Positive Topline Results From Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients With NTM Lung Disease Caused by MAC

9/5/2023

Insmed Incorporated announced positive topline results from its Phase 3 ARISE study of ARIKAYCE in patients with newly diagnosed or recurrent nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex who had not started antibiotics.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - August 4, 2023

8/4/2023

Insmed Incorporated today announced the granting of inducement awards to 46 new employees.
Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update

8/3/2023

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023

7/20/2023

Insmed Incorporated today announced that it will release its second-quarter 2023 financial results on Thursday, August 3, 2023.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 7, 2023

7/7/2023

Insmed Incorporated today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference

6/7/2023

Insmed Incorporated today announced that management will present in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA , on Wednesday, June 14, 2023.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 6, 2023

6/6/2023

Insmed Incorporated today announced the granting of inducement awards to 34 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee.
Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"

5/8/2023

Insmed Incorporated today announced progress across its early-stage research programs, which will be discussed in greater detail this morning at the Company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 05, 2023

5/5/2023

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 18 new employees.
Insmed Reports First Quarter 2023 Financial Results and Provides Business Update

5/4/2023

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
Insmed to Host Investor and Analyst Event on May 8, 2023

4/24/2023

Insmed Incorporated today announced that it will host an investor and analyst event on Monday, May 8, 2023.
Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023

4/20/2023

Insmed Incorporated today announced that it will release its first quarter 2023 financial results on Thursday, May 4, 2023.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 06, 2023

4/6/2023

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 24 new employees.
Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis

3/31/2023

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that adult patient enrollment is complete as of today in its pivotal ASPEN study of brensocatib.
Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference

3/24/2023

Insmed Incorporated (Nasdaq:INSM) today announced that eight presentations across three of its pillars—ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP)—will be shared at the American Thoracic Society (ATS) 2023 International Conference, taking place May 19-24, 2023, in Washington, D.C.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 03, 2023

3/3/2023

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 17 new employees.